There is controversy about the prognostic value of CXCR4 overexpression in different tumors, and although there are numerous related studies, Zhao et al. provided a negligible association between CXCR4 and clinical outcome in some tumor types such as breast cancer, lung cancer, or pancreatic cancer [21]. This evidence concerns the gene CXCR4 and lung carcinoma.